FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to a method for the treatment of bladder cancer. For this purpose, a patient with bladder cancer is instilled in the bladder with a composition containing: a) antibodies against PD-L1 or antibodies against PD-1; and b) composite hexyl 5-ALA-ester or its pharmaceutically acceptable salt. After the instillation of the specified composition in the bladder, the inner part of the bladder is subjected to the impact of white light, blue light, or red light.
EFFECT: invention provides for the effective treatment of bladder cancer.
18 cl
| Title | Year | Author | Number |
|---|---|---|---|
| NEO-ADJUVANT THERAPY FOR BLADDER CANCER | 2016 |
|
RU2783177C2 |
| METHOD OF PHOTODYNAMIC THERAPY (PDT) OF BLADDER CANCER | 2016 |
|
RU2745194C2 |
| CHROMOGRANIN A AS MARKER OF BLADDER CANCER | 2017 |
|
RU2785737C2 |
| METHOD FOR TREATMENT OF CANCER OF LOWER PATHWAY UROTHELIUM | 2017 |
|
RU2764747C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
| METHOD FOR TREATING COMPLICATED FORMS OF URINARY BLADDER CANCER | 2003 |
|
RU2257856C1 |
| METHOD OF TREATMENT IN CASE OF URINARY BLADDER CANCER | 2010 |
|
RU2457846C2 |
